抗Human SPARC抗体(Anti-Human SPARC antibody)
掲載日情報:2018/11/26 現在Webページ番号:30122
Human SPARCに対する抗体(Anti-Human SPARC )です。
※ 本製品は研究用です。研究用以外には使用できません。
追加しました。
価格
[在庫・価格 :2024年05月17日 00時01分現在]
詳細 | 商品名 |
|
文献数 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Anti-Human SPARC MAb (Clone 122511) |
|
2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-Human SPARC MAb (Clone 122511) |
|
2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anti-Human SPARC MAb (Clone 122511) |
|
2 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
[在庫・価格 :2024年05月17日 00時01分現在]
Anti-Human SPARC MAb (Clone 122511)
文献数: 2
- 商品コード:MAB941-100
- メーカー:RSD
- 包装:100μg
- 価格:¥100,000
- 在庫:無(未発注)
- 納期:10日程度 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等:
Anti-Human SPARC MAb (Clone 122511)
文献数: 2
- 商品コード:MAB941-500
- メーカー:RSD
- 包装:500μg
- 価格:¥232,000
- 在庫:無(未発注)
- 納期:10日程度 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等:
説明文 |
別名:Basement-membrane protein 40 クローン:122511 Genbank No: 6678 Protein Accession No: P09486 |
||||||
---|---|---|---|---|---|---|---|
別包装品 | 別包装品あり | ||||||
法規制等 | |||||||
保存条件 | -20℃ | 法規備考 | |||||
抗原種 | 免疫動物 | Mouse | |||||
交差性 | Human | 適用 | ELISA,FCM,IHC | ||||
標識 | Unlabeled | 性状 | Protein A/G Affinity Purified | ||||
吸収処理 | クラス | IgG | |||||
クロナリティ | Monoclonal | フォーマット | |||||
掲載カタログ |
|
||||||
製品記事 |
抗幹細胞マーカー抗体/抗胚性幹細胞マーカー抗体 |
||||||
関連記事 |
Anti-Human SPARC MAb (Clone 122511)
文献数: 2
- 商品コード:MAB941-SP
- メーカー:RSD
- 包装:25μg
- 価格:¥30,000
- 在庫:無(未発注)
- 納期:2~3週間 ※※ 表示されている納期は弊社に在庫がなく、取り寄せた場合の目安納期となります。
- 法規制等:
追加しました。
Product Details
Species Reactivity | Human |
---|---|
Label | Unconjugated |
Immunogen | Mouse myeloma cell line NS0-derived recombinant human SPARCAla18-Ile303Accession # P09486 |
Source | Monoclonal Mouse IgG1 Clone # 122511 |
Purification | Protein A or G purified from hybridoma culture supernatant |
Specificity | Detects human SPARC/Osteonectin in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant mouse SPARC/Osteonectin is observed. |
追加しました。
Applications and Data
Recommended Concentration | Sample | |
Immunohistochemistry | 8-25 µg/mL | See below |
CyTOF-ready | Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation. | |
Intracellular Staining by Flow Cytometry | 0.25 µg/106 cells | See below |
追加しました。
Related Product & Information
Background | SPARC |
---|---|
background_content | Background: SPARC SPARC, an acronym for “secreted protein, acidic and rich in cysteine”, is also known as osteonectin or BM-40 (1-5). It is the founding member of a family of secreted matricellular proteins with similar domain structure. The 286 amino acid (aa), 43 kDa protein contains an N-terminal acidic region that binds calcium, a follistatin domain that contains Kazal-like sequences, and a C-terminal extracellular calcium (EC) binding domain with two EF-hand motifs (1-5). Crystal structure modeling shows that residues implicated in cell binding, inhibition of cell spreading, and disassembly of focal adhesions cluster on one face of SPARC, while a collagen binding epitope and an N-glycosylation site are opposite this face (6). SPARC is produced by fibroblasts, capillary endothelial cells, platelets and macrophages, especially in areas of tissue morphogenesis and remodeling (3, 7). SPARC shows context-specific effects, but generally inhibits adhesion, spreading and proliferation, and promotes collagen matrix formation (3-5). For endothelial cells, SPARC disrupts focal adhesions and binds and sequesters PDGF and VEGF (3-5). SPARC is abundantly expressed in bone, where it promotes osteoblast differentiation and inhibits adipogenesis (5, 8). SPARC is potentially cleaved by metalloproteinases, producing an angiogenic peptide that includes the copper-binding sequence KGHK (7). Paradoxically, SPARC is highly expressed in many tumor types undergoing an endothelial to mesenchymal transition; its expression, however, mainly decreases the likelihood of metastasis and confers sensitivity to chemotherapy and radiation (4, 9-11). Stabilin-1, which is expressed on alternately activated macrophages, is the first SPARC receptor to be identified. It binds the SPARC EC domain and mediates endocytosis for degradation (12). Mature human SPARC shows 92%, 92%, 97%, 99%, 96% and 85% aa identity with mouse, rat, canine, bovine, porcine and chick SPARC, respectively. |
追加しました。
Citations
- Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis
Authors: E Borazanci, SZ Millis, J Kimbrough, N Doll, D Von Hoff, RK Ramanathan
J Gastrointest Oncol, 2017;8(1):164-172.
Species: Human
Sample Type: Whole Tissue
Application: IHC-P - Insulin-like growth factor binding protein-4 (IGFBP-4) is a novel anti-angiogenic and anti-tumorigenic mediator secreted by dibutyryl cyclic AMP (dB-cAMP)-differentiated glioblastoma cells.
Authors: Moreno MJ, Ball M, Andrade MF, McDermid A, Stanimirovic DB
Glia, 2006;53(8):845-57.
Species: Human
Sample Type: Cell Culture Supernates
Application: ELISA Development - Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach.
Authors: Gronborg M, Kristiansen TZ, Iwahori A, Chang R, Reddy R, Sato N, Molina H, Jensen ON, Hruban RH, Goggins MG, Maitra A, Pandey A
Mol. Cell Proteomics, 2006;5(1):157-71.
Species: Human
Sample Type: Cell Lysates
Application: WB
追加しました。
製品情報は掲載時点のものですが、価格表内の価格については随時最新のものに更新されます。お問い合わせいただくタイミングにより製品情報・価格などは変更されている場合があります。
表示価格に、消費税等は含まれていません。一部価格が予告なく変更される場合がありますので、あらかじめご了承下さい。